UB Paderborn / Katalog / Suche / in CDI

Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study

American journal of respiratory and critical care medicine, 2018-12, Vol.198 (12), p.1559-1569

2018

Volltextzugriff (PDF)

Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease

American journal of respiratory and critical care medicine, 2017-03, Vol.195 (6), p.814-823

2017

Volltextzugriff (PDF)

Exosomal Transport of Hepatocyte‐Derived Drug‐Modified Proteins to the Immune System

Hepatology (Baltimore, Md.), 2019-11, Vol.70 (5), p.1732-1749

2019

Volltextzugriff (PDF)

Pulmonary Deposition and Elimination of Liposomal Amikacin for Inhalation and Effect on Macrophage Function after Administration in Rats

Antimicrobial agents and chemotherapy, 2016-11, Vol.60 (11), p.6540-6549

2016

Volltextzugriff (PDF)

Examining the Effect of Residual Amikacin on Sputum Culture for Nontuberculous Mycobacteria

American journal of respiratory and critical care medicine, 2018-01, Vol.197 (2), p.267-269

2018

Volltextzugriff (PDF)

Assessing technical and biological variation in SWATH-MS-based proteomic analysis of chronic lymphocytic leukaemia cells

Scientific reports, 2021-02, Vol.11 (1), p.2932-2932, Article 2932

2021

Volltextzugriff (PDF)

Total Proteome Analysis Identifies Migration Defects as a Major Pathogenetic Factor in Immunoglobulin Heavy Chain Variable Region (IGHV)-unmutated Chronic Lymphocytic Leukemia[S]

Molecular & cellular proteomics, 2015-04, Vol.14 (4), p.933-945

2015

Volltextzugriff (PDF)

Proteomic analysis of B-cell receptor signaling in chronic lymphocytic leukaemia reveals a possible role for kininogen

Journal of proteomics, 2013-10, Vol.91, p.478-485

2013

Volltextzugriff (PDF)

Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: Current status

Cancer letters, 2010-08, Vol.294 (1), p.13-24

2010

Volltextzugriff (PDF)

COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines

Lung cancer (Amsterdam, Netherlands), 2010-02, Vol.67 (2), p.160-165

2010

Volltextzugriff (PDF)

Stability and Consistency of Treatment Effect With Liposomal Amikacin for Inhalation (LAI) as Add-on Therapy in Patients With Pulmonary Nontuberculous Mycobacterial (PNTM) Infection

Chest, 2016-10, Vol.150 (4), p.1235A-1235A

2016

Volltextzugriff (PDF)

Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients

Current Alzheimer research, 2009-02, Vol.6 (1), p.4

2009

Volltextzugriff (PDF)

Case Report of a Patient With Treatment-Refractory Nontuberculous Mycobacteria (NTM) Lung Infection Treated With Once Daily (QD) Liposomal Amikacin for Inhalation (LAI)

Chest, 2015-10, Vol.148 (4), p.162A-162B

2015

Volltextzugriff (PDF)

Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697

International journal of oncology, 2013-03, Vol.42 (3), p.1088-1092

2013

Volltextzugriff (PDF)

Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis

Alimentary pharmacology & therapeutics, 2020-04, Vol.51 (8), p.750-759

2020

Volltextzugriff (PDF)

Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial

Clinical gastroenterology and hepatology, 2022-11, Vol.20 (11), p.2485-2494.e15

2022

Volltextzugriff (PDF)

Relative risk of all-cause mortality in patients with nontuberculous mycobacterial lung disease in a US managed care population

Respiratory medicine, 2018-12, Vol.145, p.80-88

2018

Volltextzugriff (PDF)

964 FLUTICASONE PROPRIONATE ORAL DISINTEGRATING TABLET, APT-1011, IMPROVES FIBROSTENOTIC FEATURES OF STRICTURES AND GRADE 2/3 RINGS IN SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS (EOE)

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-230-S-230

2024

Volltextzugriff (PDF)

965 FLUTICASONE PROPIONATE ORAL DISINTEGRATING TABLET, APT-1011, LEADS TO A GREATER COMPLETE SYMPTOMATIC RESPONSE RATE COMPARED TO PLACEBO IN SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS (EOE)

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-230-S-231

2024

Volltextzugriff (PDF)

S465 Development and Content Validity of the PROSE Daily Diary to Measure Dysphagia Episodes in Adults and Adolescents With Eosinophilic Esophagitis

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S205-S206

2021

Volltextzugriff (PDF)

Fr172 LOW RATES OF GLUCOCORTICOID-RELATED ADVERSE EFFECTS WITH LONG-TERM TREATMENT OF EOSINOPHILIC ESOPHAGITIS WITH FLUTICASONE PROPIONATE ORALLY DISINTEGRATING TABLET (APT-1011): RESULTS FROM 52 WEEKS OF EXPOSURE IN A PHASE 2B TRIAL

Gastroenterology (New York, N.Y. 1943), 2021-05, Vol.160 (6), p.S-248-S-249

2021

Volltextzugriff (PDF)

540 FLUTICASONE PROPIONATE ORALLY DISINTEGRATING TABLET (APT-1011) IMPROVES HISTOLOGIC, ENDOSCOPIC AND SYMPTOMATIC RESPONSES IN EOSINOPHILIC ESOPHAGITIS PATIENTS WITH FIBRO-STENOTIC FEATURES: RESULTS FROM A PHASE 2B TRIAL

Gastroenterology (New York, N.Y. 1943), 2021-05, Vol.160 (6), p.S-111-S-112

2021

Volltextzugriff (PDF)

S0345 Safety and Efficacy of Long-Term Treatment of EoE With Fluticasone Propionate Orally Disintegrating Tablet (APT-1011): Results From 40 Weeks Treatment in a Phase 2b Randomized Double-Blind Placebo-Controlled Trial

The American journal of gastroenterology, 2020-10, Vol.115 (1), p.S169-S170

2020

Volltextzugriff (PDF)

Mo1182 AN EPISODE-BASED, PATIENT-REPORTED OUTCOME MEASURE OF DYSPHAGIA ACCURATELY CAPTURES RESPONSE TO TREATMENT WITH APT-1011 IN A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIAL IN ADULTS WITH EOSINOPHILIC ESOPHAGITIS

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.S-817-S-817

2020

Volltextzugriff (PDF)

Mo1184 AN EPISODE-BASED PATIENT-REPORTED OUTCOME MEASURE OF DYSPHAGIA EXPERIENCE IS FEASIBLE AND NOT BURDENSOME FOR PATIENTS WITH EOSINOPHILIC ESOPHAGITIS

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.S-818-S-818

2020

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study

Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease

Exosomal Transport of Hepatocyte‐Derived Drug‐Modified Proteins to the Immune System

Pulmonary Deposition and Elimination of Liposomal Amikacin for Inhalation and Effect on Macrophage Function after Administration in Rats

Examining the Effect of Residual Amikacin on Sputum Culture for Nontuberculous Mycobacteria

Assessing technical and biological variation in SWATH-MS-based proteomic analysis of chronic lymphocytic leukaemia cells

Total Proteome Analysis Identifies Migration Defects as a Major Pathogenetic Factor in Immunoglobulin Heavy Chain Variable Region (IGHV)-unmutated Chronic Lymphocytic Leukemia[S]

Proteomic analysis of B-cell receptor signaling in chronic lymphocytic leukaemia reveals a possible role for kininogen

Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: Current status

COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines

Stability and Consistency of Treatment Effect With Liposomal Amikacin for Inhalation (LAI) as Add-on Therapy in Patients With Pulmonary Nontuberculous Mycobacterial (PNTM) Infection

Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients

Case Report of a Patient With Treatment-Refractory Nontuberculous Mycobacteria (NTM) Lung Infection Treated With Once Daily (QD) Liposomal Amikacin for Inhalation (LAI)

Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697

Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis

Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial

Relative risk of all-cause mortality in patients with nontuberculous mycobacterial lung disease in a US managed care population

964 FLUTICASONE PROPRIONATE ORAL DISINTEGRATING TABLET, APT-1011, IMPROVES FIBROSTENOTIC FEATURES OF STRICTURES AND GRADE 2/3 RINGS IN SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS (EOE)

965 FLUTICASONE PROPIONATE ORAL DISINTEGRATING TABLET, APT-1011, LEADS TO A GREATER COMPLETE SYMPTOMATIC RESPONSE RATE COMPARED TO PLACEBO IN SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS (EOE)

S465 Development and Content Validity of the PROSE Daily Diary to Measure Dysphagia Episodes in Adults and Adolescents With Eosinophilic Esophagitis

Fr172 LOW RATES OF GLUCOCORTICOID-RELATED ADVERSE EFFECTS WITH LONG-TERM TREATMENT OF EOSINOPHILIC ESOPHAGITIS WITH FLUTICASONE PROPIONATE ORALLY DISINTEGRATING TABLET (APT-1011): RESULTS FROM 52 WEEKS OF EXPOSURE IN A PHASE 2B TRIAL

540 FLUTICASONE PROPIONATE ORALLY DISINTEGRATING TABLET (APT-1011) IMPROVES HISTOLOGIC, ENDOSCOPIC AND SYMPTOMATIC RESPONSES IN EOSINOPHILIC ESOPHAGITIS PATIENTS WITH FIBRO-STENOTIC FEATURES: RESULTS FROM A PHASE 2B TRIAL

S0345 Safety and Efficacy of Long-Term Treatment of EoE With Fluticasone Propionate Orally Disintegrating Tablet (APT-1011): Results From 40 Weeks Treatment in a Phase 2b Randomized Double-Blind Placebo-Controlled Trial

Mo1182 AN EPISODE-BASED, PATIENT-REPORTED OUTCOME MEASURE OF DYSPHAGIA ACCURATELY CAPTURES RESPONSE TO TREATMENT WITH APT-1011 IN A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIAL IN ADULTS WITH EOSINOPHILIC ESOPHAGITIS

Mo1184 AN EPISODE-BASED PATIENT-REPORTED OUTCOME MEASURE OF DYSPHAGIA EXPERIENCE IS FEASIBLE AND NOT BURDENSOME FOR PATIENTS WITH EOSINOPHILIC ESOPHAGITIS

Suchergebnisse filtern